Risk factor
Good trading liquidity
Profitability factor
Favourable analyst view
About
Operating as a Contract Development and Manufacturing Organization (CDMO), ST Pharm Co. Ltd. provides pharmaceutical and non-pharmaceutical products within South Korea. Its comprehensive Chemistry, Manufacturing, and Controls (CMC) services include the development of analytical methods, in-house reference standard testing, qualification and validation of analytical techniques, detailed analytical characterization, and robust CMC documentation. The company also specializes in oligonucleotide-based products, such as antisense oligonucleotides, siRNA, miRNA, aptamers, CpG, and decoy molecules, as well as monomers and phosphoramidites. Additionally, ST Pharm manufactures generic Active Pharmaceutical Ingredients (APIs) for a broad range of therapeutic areas, including anti-cancer, anti-coagulant, anti-fungal, anti-hyperlipidemia, anti-hypertensive, anti-tuberculosis, asthma, COPD, cough suppression, diabetes mellitus, epilepsy, hepatitis B, and erectile dysfunction medications, along with ingredients for MRI contrast agents. Beyond its pharmaceutical focus, the firm supplies components for secondary batteries, electronic materials, and polymer catalysts. Founded in 1983 as Samchully Pharmaceutical Company Ltd., ST Pharm Co. Ltd. is headquartered in Seoul, South Korea.
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA
Target Price
The average target price of 237690.KQ is 180678 and suggests 99.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation